Survival benefit with 'fully human' EGFR antibody Necitumumab in squamous NSCLC

Results of a 1,093-person phase III clinical trial of the drug Necitumumab (IMC-11F8) combined with chemotherapies gemcitabine and cisplatin against stage IV squamous non-small cell lung cancer have been reported by researchers. With addition of necitumumab, median overall survival was 11.5 months compared with median survival of 9.9 months with the two chemotherapies alone.